IJCRR - 10(13), July, 2018
Pages: 05-10
Validated RP-HPLC Method for Quantification of Paclitaxel in Human Plasma – Eliminates Negative Influence of Cremophor El
Author: Hindu Kalluru, Vinodhini C., Satish Srinivas K., Surulivel Rajan M., Chitra K., Mangathayaru K.
Category: Healthcare
[Download PDF]
Abstract:
Background: Literature reports innumerable methods for quantification of paclitaxel in biological matrices. Most of these involve complicated extraction procedures like solid phase extraction, separate procedure for elimination of interference of Cremophor El, advanced and expensive instruments.
Objectives: The objective of the present research work is to develop and validate a simple, rapid, sensitive, economic and reproducible reverse phase – high performance liquid chromatography method for the estimation of paclitaxel concentration in human plasma that eliminates negative influence of Cremophor El on recovery of paclitaxel.
Methods: Chromatographic separation of paclitaxel was carried out using C18 column (150 × 4.6 mm i.d., 4μm particle size, Waters, Australia) with 60% acetonitrile, 40% of 10mM ammonium acetate buffer solution and 0.1% formic acid as a mobile phase at a flow rate of 1.0mL/min at ambient temperature. Validation was performed as per ICH Q2 guidelines.
Results: In this system the retention time was 3min. The detection limit was 5ng/mL and limit of quantification with reproducibility was 15ng/mL. Plasma samples were extracted using single solvent (tertiary – Butyl Methyl Ether) liquid- liquid extraction with a recovery of 96-99%. Robustness of the method was established with variation in flow rate, detection wave length and mobile phase composition. Stability of paclitaxel during the study period was studied and found to be stable.
Conclusion: The developed method is easy to perform, quick, reproducible with good recovery without negative influence of Cremophor El and applicable to quantify paclitaxel in regular clinical practice for individualization of the therapies.
Keywords: Paclitaxel, Cremophor El, Single solvent extraction, Bioanalytical
Citation:
Hindu Kalluru, Vinodhini C., Satish Srinivas K., Surulivel Rajan M., Chitra K., Mangathayaru K.. Validated RP-HPLC Method for Quantification of Paclitaxel in Human Plasma – Eliminates Negative Influence of Cremophor El International Journal of Current Research and Review. 10(13), July, 05-10
References:
(1) Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, et al. Taxanes: A New Class of Antitumor Agents.Cancer Investigations1995; 13 (4): 381–404.
(2) Jordan MA, Wilson L. Microtubules and Actin Filaments: Dynamic Targets for Cancer Chemotherapy. Current Opinion in Cell Biology 1998; 123–130.
(3) Jordan MA, Wilson L. Microtubules as a Target for Anticancer Drugs. Nature Reviews Cancer 2004; 4 (4): 253–265.
(4) Gligorov J, Lotz JP. Preclinical Pharmacology of the Taxanes: Implications of the Differences. Oncologist 2004; 9 Suppl 2 (suppl 2): 3–8.
(5) Steed H, Sawyer MB. Pharmacology, Pharmacokinetics and Pharmacogenomics of Paclitaxel. Pharmacogenomics2007; 8 (7): 803–815.
(6) Gerritsen-van Schieveen P, Royer B. Level of Evidence for Therapeutic Drug Monitoring of Taxanes. Fundamentals and Clinical Pharmacology2011; 25 (4): 414–424.
(7) Krens SD, McLeod HL, Hertz DL. Pharmacogenetics, Enzyme Probes and Therapeutic Drug Monitoring as Potential Tools for Individualizing Taxane Therapy. Pharmacogenomics 2013; 14 (5): 555–574.
(8) Sparreboom A, Zuylen L Van, Brouwer E, Loos WJ, Bruijn P De, Gelderblom H et al. Cremophor EL-Mediated Alteration of Paclitaxel Distribution in Human Blood?: Clinical Pharmacokinetic Implications.Cancer Research 1999; 1454–1457.
(9) Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H. High Sensitivity Assays for Docetaxel and Paclitaxel in Plasma Using Solid-Phase Extraction and High-Performance Liquid Chromatography with UV Detection. BMC Clinical Pharmacology 2006; 6 (1): 2.
(10)HendrikxJJMA, Rosing H, SchinkelAH, Schellens JHM, Beijnen JH. Quantification of Taxanes in Biological Matrices: A Review of Bioanalytical Assays and Recommendations for Development of New Assays. Bioanalysis 2014; 6 (7): 993–1010.
(11) Palmas RA, Monteiro J, Fresco P. Analytical Methods for Taxanes Quantification in Diluted Formulations and Biological Samples and Their Applications in Clinical Practice. International Journal of Pharmacy and Pharmaceutical Sciences 2014; 6 (6): 17–23.
(12) Khan I, Iqbal Z, Khan A, Hassan M, Nasir F, Raza A et al. A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib and paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci., 2016;DOI: 10.1016/j.jchromb.2016.08.029.
(13) Yonemoto H, Ogino S, Nakashima MN, Wada M, Nakashima K. Determination of Paclitaxel in Human and Rat Blood Samples after Administration of Low Dose Paclitaxel by HPLC-UV Detection. Biomedical Chromatography 2007; 21: 310-317.
(14)https://www.gmp-compliance.org/guidelines/gmp-guideline/ich-q2r1-validation-of-analytical-procedures-text-and-methodology (Last accessed: October 28, 2017)
(15) Bhaskar V. Identification and Reduction of Matrix Effects Caused by Cremophor EL in Bioanalysis Using Liquid Chromatography/Tandem Mass Spectrometry. Analytical and Bioanalytical Techniques 2013; 4 (3): 167.
|